Baxter International Inc. (BAX)
-NYSE 72.94 
1.09(1.52%) 18 May 04:00 SGT|After Hours
:
74.12 1.18 (1.62%) 18 May 07:59 SGT
| Prev Close: | 71.85 |
|---|
| Open: | 72.14 |
|---|
| Bid: | 73.90 x 100 |
|---|
| Ask: | 74.89 x 200 |
|---|
| 1y Target Est: | 74.80 |
|---|
| Beta: | 0.8 |
|---|
| Next Earnings Date: | 15-Jul-13 |
|---|
| Day's Range: | 71.95 - 73.40 |
|---|
| 52wk Range: | 48.98 - 73.40 |
|---|
| Volume: | 7,486,212 |
|---|
| Avg Vol (3m): | 3,556,250 |
|---|
| Market Cap: | 39.53B |
|---|
| P/E (ttm): | 17.62 |
|---|
| EPS (ttm): | 4.14 |
|---|
| Div & Yield: | 1.96 (2.80%) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Final Glance: Medical Devices companiesAP(Sat, 18 May)
- Final Glance: Pharmaceuticals companiesAP(Sat, 18 May)
- Midday Glance: Pharmaceuticals companiesAP(Sat, 18 May)
- Midday Glance: Medical Devices companiesAP(Sat, 18 May)
- Early Glance: Medical Devices companiesAP(Fri, 17 May)
- Early Glance: Pharmaceuticals companiesAP(Fri, 17 May)
- Halozyme rises on pancreatic cancer drug studyAP(Fri, 17 May)
- Halozyme rises on prostate cancer drug studyAP(Fri, 17 May)
- Baxter drug fails to slow Alzheimer's in big studyAP(Tue, 7 May)
- Baxter 1Q profit falls 6 percent on Gambro costsAP(Thu, 18 Apr)
Key Statistics
| Forward P/E (1 yr): | 14.11 |
|---|
| P/S (ttm): | 2.73 |
|---|
| Ex-Dividend Date: | 05-Jun-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 4.65 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.13 |
|---|
| Mean Recommendation*: | 2.2 |
|---|
| PEG Ratio (5 yr expected): | 1.71 |
|---|
Business Summary
Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
View More